$6.80 -0.46 (%) Celldex Therapeutics Inc - NASDAQ

Feb. 8, 2016 | 01:20 PM

Partner Headlines

  1. Long-term Survival Benefit Demonstrated in Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma

    Benzinga | Nov. 20, 2015 | 14:32PM EST
  2. Celldex Therapeutics Reports Presentation of Varlilumab Mechanism Data at SITC Annual Meeting '15

    Benzinga | Nov. 6, 2015 | 07:06AM EST
  3. Vaccinex Announces Publication of Results From a Phase I Trial of Anti-Semaphorin 4D Antibody, VX15/2503, in Patients With Advanced Solid Tumors

    Benzinga | Oct. 20, 2015 | 13:18PM EST
  4. Morning Market Losers

    Benzinga | Aug. 11, 2015 | 10:03AM EST
  5. Monday's After-Hours Movers Led By Rackspace, Shake Shack And Take-Two

    Benzinga | Aug. 10, 2015 | 17:12PM EST
  6. Cantor Fitzgerald and Brean Capital Positive on Celldex Therapeutics Following Positive Data ...

    GuruFocus | Jun. 1, 2015 | 17:36PM EST
  7. Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG ...

    GuruFocus | Jun. 1, 2015 | 17:15PM EST
  8. Morning Market Losers

    Benzinga | Jun. 1, 2015 | 10:25AM EST
  9. US Stock Futures Signal Higher Start On Wall Street

    Benzinga | Apr. 20, 2015 | 08:08AM EST
  10. Celldex's Varlilumab Demonstrates Synergistic Anti-Tumor Activity with PD-1 Signaling Blockade in Preclinical Studies

    Benzinga | Apr. 20, 2015 | 08:02AM EST
  11. Biotech Stocks Moving Higher

    Benzinga | Feb. 23, 2015 | 15:35PM EST
  12. Morning Market Gainers

    Benzinga | Feb. 23, 2015 | 09:44AM EST
  13. Monday's #PreMarket Movers: Spectrum Pharmaceuticals, Cyberark Software Trending Down

    Benzinga | Feb. 23, 2015 | 08:57AM EST
  14. Stocks That Battle Cancer Were The Best-Performing Biotechs In January

    Benzinga | Jan. 30, 2015 | 13:03PM EST
  15. Here's The Last Biotech Breakout

    Benzinga | Nov. 26, 2014 | 12:01PM EST
  16. This Biotech Stock Is Ready To Run

    Benzinga | Nov. 19, 2014 | 18:12PM EST
  17. Mid-Day Losers From November 18: Omega Protein, Urban Outfitters, Celldex Therapeutics, Amicus Therapeutics, Inter Parfums

    Benzinga | Nov. 18, 2014 | 12:58PM EST
  18. Midday Gainers From November 17: Celldex Therapeutics, Amicus Therapeutics, Baker Hughes, Allergan

    Benzinga | Nov. 17, 2014 | 12:34PM EST
  19. Celldex Therapeutics Jumps 25% Amid Brain Cancer Study

    Benzinga | Nov. 17, 2014 | 10:47AM EST
  20. Mid-Morning Market Update: Markets Edge Lower; Halliburton To Acquire Baker Hughes For $34.6 Billion

    Benzinga | Nov. 17, 2014 | 10:42AM EST
  21. Morning Market Movers

    Benzinga | Nov. 17, 2014 | 09:51AM EST
  22. Benzinga's Top #PreMarket Gainers

    Benzinga | Nov. 17, 2014 | 08:08AM EST
  23. Oncothyreon And Celldex Therapeutics Announce Initiation Of Combination Immunotherapy Clinical Trial Of ONT-10 and Varlilumab

    Benzinga | Nov. 10, 2014 | 16:10PM EST
  24. Celldex Therapeutics Breaks Resistance

    Benzinga | Oct. 16, 2014 | 15:10PM EST
  25. 5 Companies Developing New Cancer Drugs

    Benzinga | Aug. 19, 2014 | 13:20PM EST
  26. 5-Star Biotech Stock Watch: Celldex Therapeutics

    Benzinga | Jun. 25, 2014 | 15:30PM EST
  27. Top Healthcare Movers For June 9, 2014

    Benzinga | Jun. 9, 2014 | 14:27PM EST
  28. Mid-Afternoon Market Update: Markets Head Downward As Commodities Continue To Show Strength

    Benzinga | May. 14, 2014 | 15:49PM EST
  29. Celldex's Phase 1 Study of CDX-1401 Published in Science Translational Medicine

    Benzinga | Apr. 16, 2014 | 14:02PM EST
  30. Mid-Afternoon Market Update: Markets Recover Slightly As Healthcare Stocks Continue to Show Weakness

    Benzinga | Mar. 24, 2014 | 15:33PM EST
  31. Mid-Day Market Update: NASDAQ Tumbles 1.65%; Nu Skin Shares Surge After AIC China Review Update

    Benzinga | Mar. 24, 2014 | 12:48PM EST
  32. Mid-Morning Market Update: Markets Mostly Lower; ReneSola Swings To Q4 Profit

    Benzinga | Mar. 24, 2014 | 10:35AM EST
  33. Morning Market Losers

    Benzinga | Mar. 3, 2014 | 10:23AM EST
  34. Earnings Scheduled For March 3, 2014

    Benzinga | Mar. 3, 2014 | 04:42AM EST
  35. Trade of the Day: Long CLDX

    Benzinga | Jan. 2, 2014 | 15:31PM EST
  36. Celldex Therapeutics Prices 7M Share Offering at $24.50/Share

    Benzinga | Dec. 4, 2013 | 21:00PM EST
  37. Celldex Therapeutics Announces 6.5M Share Offering

    Benzinga | Dec. 3, 2013 | 16:05PM EST
  38. Celldex Therapeutics Initiates Accelerated Approval Study of Glembatumumab Vedotin in Patients with Triple Negative Breast Cancer

    Benzinga | Dec. 2, 2013 | 07:07AM EST
  39. Mid-Afternoon Market Update: Markets Turn Back as Momentum Stocks Drop

    Benzinga | Nov. 25, 2013 | 15:48PM EST
  40. Mid-Day Market Update: SeaDrill Drops On Downbeat Earnings; Giant Interactive Shares Spike Higher

    Benzinga | Nov. 25, 2013 | 13:04PM EST
  41. Benzinga's Top #PreMarket Losers

    Benzinga | Nov. 25, 2013 | 08:20AM EST
  42. Celldex Therapeutics Presents Positive Phase 2 Rindopepimut Data in Patients with Recurrent Glioblastoma

    Benzinga | Nov. 24, 2013 | 15:37PM EST
  43. Downside Protection For Regeneron Pharmaceuticals

    Benzinga | Nov. 15, 2013 | 13:34PM EST
  44. Celldex Announces Publication of Preliminary Data from Phase 2 ReACT Study of Rindopepimut Vaccine Plus Bevacizumab

    Benzinga | Nov. 11, 2013 | 07:06AM EST
  45. Mid-Afternoon Market Update: Twitter IPO a Wild Success as Markets Slide

    Benzinga | Nov. 7, 2013 | 15:20PM EST
  46. Celldex Therapeutics' CDX-1127 Well Tolerated and Demonstrates Anti-Tumor Activity in Phase 1 Dose-Escalation Study

    Benzinga | Nov. 7, 2013 | 08:04AM EST
  47. Celldex to Present Dat at SITC, SNO Annual Meetings

    Benzinga | Oct. 21, 2013 | 12:31PM EST
  48. Pharmaceutical Industry Expected To Collect Billions From Obamacare

    Benzinga | Oct. 2, 2013 | 12:51PM EST
  49. Market Wrap For Monday, September 23: Markets Unmoved Despite Kenyan Terror

    Benzinga | Sep. 23, 2013 | 16:19PM EST
  50. Mid-Afternoon Market Update: Celldex Therapeutics Rallies as Pandora Drops

    Benzinga | Sep. 23, 2013 | 15:39PM EST
Trading Center